EuroBiotech: More articles of note

newspapers
(Pixabay)

> Servier secured an option on Oncodesign’s LRRK2 Parkinson’s disease program. Oncodesign will take the program up to the receipt of IND status, at which point Servier will decide whether to pick up the candidate. Statement 

> FDA cleared Genfit to start a phase 2 trial of elafibranor in pediatric NASH patients. Release  

> ProQR dosed the first patient in its phase 1/2 trial of QR-421a in patients with Usher syndrome type 2. Statement  

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

> Erytech confirmed it is on track to deliver interim data from its phase 3 pancreatic cancer trial in the first half of next year, despite taking longer than expected to get clearance to enroll patients in the U.S. Faster-than-expected enrollment in Europe has mitigated the effect of the delay. Release 

> Shares in GeNeuro jumped around 30% following the release of more data from its phase 2b multiple sclerosis trial. The stock is still well down on the highs it hit before a clinical setback in 2017. Statement 

> Herantis Pharma raised €5.8 million ($6.6 million). The Finnish drug developer will use the money to prepare for phase 2 and 3 trials of its treatments for lymphedema and Parkinson’s disease. Release 

Suggested Articles

The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.

The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.

Phase 1 data for PhaseBio's Brilinta reversal agent showed the drug quickly reversed the effects of Brilinta without causing serious side effects.